Gyre Therapeutics, Inc. financials

GYRE CIK 0001124105

Source: EDGAR filings · Built 2026-06-02T03:10:54Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -180.00K -5.96M 17.38M 5.69M -84.59M
EBITDA 13.97M 17.71M -66.16M 10.29M -87.60M -57.23M
Working Capital 84.08M 45.27M 37.17M 37.41M 37.31M 71.71M
Net Debt -36.13M -10.21M -33.10M -25.14M -41.96M -28.72M
Gross Margin 95.35% 96.33% 95.91% 95.31%
Operating Margin 9.85% 15.28% -59.26% 9.00% -1197.79% -273.87%
Net Margin 8.47% 16.92% -75.35% 4.22% -1198.32% -268.48%
Return on Equity (ROE) 9.32% 28.27% 540.06% 10.15% -214.01% -73.93%
Return on Assets (ROA) 5.95% 14.27% -73.35% 5.09% -157.98% -59.30%
Current Ratio 5.60× 3.32× 2.85× 4.06× 3.63× 5.03×
Debt-to-Equity 0.01× 0.03× -0.03× 0.00× 0.06× 0.02×
Effective Tax Rate 31.56% 22.91% -11.06% 54.16%
Cash Conversion Ratio 0.10× -0.20× -0.30× 2.48× 0.95× 0.98×
Accruals Ratio 0.05× 0.17× -0.96× -0.08× -0.08× -0.01×
SBC % of Revenue 6.14% 0.79% 6.42% 13.07% 46.40% 17.31%
CapEx Coverage 0.85× -1.57× 3.04× 2.14× -99.83×
Free Cash Flow Per Share $-0.00 $-0.06 $0.26 $0.08 $-2.76

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 353.00× 242.00× 265.00×
P/FCF 97.35× 105.72×
FCF Yield 1.03% 0.95%
EV / EBITDA 43.57× 58.38× 0.83×
P/S 5.53× 9.87× 17.34× 0.33× 3.90× 6.66×
P/B 6.08× 16.49× 0.79× 0.70× 1.83×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 116.59M 105.76M 113.45M 102.29M 7.34M 20.95M
Cost of Goods and Services Sold 5.42M 3.88M 4.64M 4.79M
Gross Profit 101.87M 108.81M 97.50M
Research and Development Expense 13.70M 12.02M 13.78M 68.89M 52.98M
Operating Expenses 105.10M 89.59M 176.04M 88.29M 95.23M 78.32M
Operating Income (Loss) 11.49M 16.16M -67.23M 9.20M -87.89M -57.37M
Income Tax Expense (Benefit) 4.56M 5.32M 8.52M 5.10M
Net Income (Loss) Attributable to Parent 9.88M 17.90M -85.48M 4.31M -87.93M -56.24M
Earnings Per Share, Basic $0.06 $0.14 $-1.41 $0.04 $-2.87
Weighted Average Number of Shares Outstanding, Basic 89.34M 85.09M 65.83M 63.59M 30.64M
Earnings Per Share, Diluted $0.02 $0.05 $-1.41 $0.03 $-2.87
Weighted Average Number of Shares Outstanding, Diluted 103.18M 102.29M 65.83M 75.69M 30.64M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 37.07M 11.81M 33.51M 25.18M 44.35M 30.36M
Assets, Current 102.37M 64.79M 57.22M 49.65M 51.48M 89.51M
Assets 166.13M 125.41M 116.54M 84.75M 55.66M 94.85M
Liabilities, Current 18.29M 19.52M 20.05M 12.24M 14.16M 17.80M
Liabilities 23.85M 27.00M 38.06M 12.54M 14.57M 18.78M
Stockholders' Equity Attributable to Parent 106.03M 63.32M -15.83M 42.52M 41.09M 76.07M
Common Stock, Shares, Outstanding 91.31M 86.31M 76.60M 63.59M 31.41M 22.10M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 1.01M -3.64M 25.89M 10.68M -83.75M -55.05M
Payments to Acquire Property, Plant, and Equipment 1.19M 2.31M 8.52M 4.99M 839.00K
Net Cash Provided by (Used in) Investing Activities -474.00K -19.88M -19.76M -13.81M 48.19M 9.66M
Payments of Dividends 45.03M
Net Cash Provided by (Used in) Financing Activities 24.38M 2.10M 2.50M -45.01M 49.55M 60.38M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (GYRE CIK 0001124105), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ARDX

ARDELYX, INC.

GSIT

GSI Technology, Inc.

QMCO

QUANTUM CORP /DE/